TY - JOUR
T1 - A novel conditioning-free hematopoietic stem cell transplantation model in zebrafish
AU - Fraint, Ellen
AU - Norberto, María Feliz
AU - Bowman, Teresa V.
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health, National Cancer Institute (P30CA013330) (Analytical Imaging Facility [AIF] and flow cytometry facilities), National Institute of Diabetes and Digestive and Kidney Diseases (1R56DK121738-01) (T.V.B.), and National Institute of General Medical Sciences (R25-GM104547) (Postbaccalaureate Research Education Program at Albert Einstein College of Medicine) (M.F.N.); the American
Publisher Copyright:
© 2020 by The American Society of Hematology
PY - 2020/12/22
Y1 - 2020/12/22
N2 - Transplantation is the most common assay for measuring the in vivo functionality of hematopoietic stem cells (HSCs). Although various HSC transplantation strategies have been developed in zebrafish, they are underutilized because of challenges related to immune matching and preconditioning toxicity. To circumvent these limitations, we developed a simple and robust transplantation model using HSC-deficient hosts. Homozygous runx1W84X mutants are devoid of definitive hematopoietic cells, including HSCs and adaptive immune cells; thus, they require no preconditioning regimen for transplantation. Marrow cell transplantation into runx1-mutant zebrafish 2 days after fertilization significantly improved their survival to adulthood and resulted in robust, multilineage, long-lasting, serially repopulating engraftment. Furthermore, we demonstrated that engraftment into runx1 homozygous mutants was significantly higher than into runx1 heterozygotes, demonstrating that the improved transplantation success is attributable to the empty HSC niche in mutants and not just the embryonic environment. Competitive transplantation of marrow cells into runx1 mutants revealed a stem cell frequency similar to that of murine marrow cells, which demonstrates the utility of this model for quantifying HSC function. The streamlined approach and robustness of this assay will help broaden its feasibility for future high-throughput transplantation experiments in zebrafish and will enable further novel discoveries in the biology of HSCs.
AB - Transplantation is the most common assay for measuring the in vivo functionality of hematopoietic stem cells (HSCs). Although various HSC transplantation strategies have been developed in zebrafish, they are underutilized because of challenges related to immune matching and preconditioning toxicity. To circumvent these limitations, we developed a simple and robust transplantation model using HSC-deficient hosts. Homozygous runx1W84X mutants are devoid of definitive hematopoietic cells, including HSCs and adaptive immune cells; thus, they require no preconditioning regimen for transplantation. Marrow cell transplantation into runx1-mutant zebrafish 2 days after fertilization significantly improved their survival to adulthood and resulted in robust, multilineage, long-lasting, serially repopulating engraftment. Furthermore, we demonstrated that engraftment into runx1 homozygous mutants was significantly higher than into runx1 heterozygotes, demonstrating that the improved transplantation success is attributable to the empty HSC niche in mutants and not just the embryonic environment. Competitive transplantation of marrow cells into runx1 mutants revealed a stem cell frequency similar to that of murine marrow cells, which demonstrates the utility of this model for quantifying HSC function. The streamlined approach and robustness of this assay will help broaden its feasibility for future high-throughput transplantation experiments in zebrafish and will enable further novel discoveries in the biology of HSCs.
UR - http://www.scopus.com/inward/record.url?scp=85098075907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098075907&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2020002424
DO - 10.1182/bloodadvances.2020002424
M3 - Article
AN - SCOPUS:85098075907
SN - 2473-9529
VL - 4
SP - 6189
EP - 6198
JO - Blood Advances
JF - Blood Advances
IS - 24
ER -